ArticleAntimicrobial agents and chemotherapy2006
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 99 citations in OpenAlex.
- Segmental duplications and supernumerary chromosomes drive antifungal drug resistance in Candida auris.Nature communications · 2026Article
- Comparison of Six Antifungal Susceptibilities of 11Microbiology spectrum · 2022Article
- Multilocus Sequence Typing and Antifungal Susceptibility ofFrontiers in veterinary science · 2022Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- The isolation and identification of Candida glabrata from avian species and a study of the antibacterial activities of Chinese herbal medicine in vitro.Poultry science · 2021Article
- Article
- Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins.Journal of fungi (Basel, Switzerland) · 2020Review
- Antifungal Susceptibility Testing: Current Approaches.Clinical microbiology reviews · 2020Review
- Extrapolating Antifungal Animal Data to Humans - Is it reliable?Current fungal infection reports · 2020Article
- Minimal Inhibitory Concentration (MIC)-Phenomena inJournal of fungi (Basel, Switzerland) · 2019Article
- Paradoxical growth effect of caspofungin on Candida spp. sessile cells not only at high drug concentrations.The Journal of antibiotics · 2019Article
- Detection of Candida species by nested PCR method in one-humped camels (Camelus dromedarius).Tropical animal health and production · 2018Article
- Recent Insights into the Paradoxical Effect of Echinocandins.Journal of fungi (Basel, Switzerland) · 2017Review
- Caspofungin-Mediated Growth Inhibition and Paradoxical Growth in Aspergillus fumigatus Involve Fungicidal Hyphal Tip Lysis Coupled with Regenerative Intrahyphal Growth and Dynamic Changes in β-1,3-Glucan Synthase Localization.Antimicrobial agents and chemotherapy · 2017Article
- Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.Antimicrobial agents and chemotherapy · 2016Article
- [Strategies for antifungal treatment failure in intensive care units].Der Anaesthesist · 2015Review
- Mechanisms of echinocandin antifungal drug resistance.Annals of the New York Academy of Sciences · 2015Review
- Mechanisms of Antifungal Drug Resistance.Cold Spring Harbor perspectives in medicine · 2014Review
- Antifungal pharmacokinetics and pharmacodynamics.Cold Spring Harbor perspectives in medicine · 2014Review
- Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Drugs · 2014Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paradoxical growth of some Candida albicans isolates in the presence of caspofungin (CAS) in vitro has been demonstrated previously. We sought to determine whether a similar phenomenon occurred in vivo. A systemic model of candidiasis was studied in CD-1 mice by intravenous inoculation of different isolates of C. albicans. Infected animals were treated with CAS at various dosages (0.01 to 20 mg/kg) and CFU remaining in the kidneys determined. Four clinical isolates that showed paradoxical growth in vitro and one that did not were tested. Recovery of CFU from the kidneys showed that dosages of CAS at 0.1 mg/kg and above were efficacious in the reduction of C. albicans, but were not curative. Against isolates that show paradoxical growth in vitro, CAS was efficacious, but lacked dose responsiveness above 0.5 mg/kg against three of the four. One isolate, 95-68, showed paradoxical growth in vivo with significantly higher CFU recovered from mice given CAS at 20 mg/kg than those given CAS at 5 mg/kg, but the effect was not reproducible in a subsequent experiment. When CAS was given prophylactically and therapeutically, improved efficacy and cure rate were observed. Overall, these data indicate that CAS is highly efficacious against systemic murine candidiasis and a paradoxical effect was not reproducibly demonstrated in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.